Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Drug

Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 23, 2025

Boehringer Ingelheim announced that its oral selective phosphodiesterase‑4B (PDE4B) inhibitor Nerandomilast (JASCAYD®) has received formal...

Company Deals

Fosun Pharma & Helsinn Partner to Produce Fosnetupitant for Akynzeo in China

Fineline Cube Oct 23, 2025

Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Healthcare SA announced a strategic cooperation...

Company Drug

PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study

Fineline Cube Oct 23, 2025

Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase III EV‑303 (KEYNOTE‑905) trial...

Company Drug

AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA

Fineline Cube Oct 23, 2025

AbbVie (NYSE: ABBV) announced positive topline data from its Phase IIIb/IV head‑to‑head trial, SELECT‑SWITCH, comparing upadacitinib...

Company Drug

Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC

Fineline Cube Oct 23, 2025

China‑based Harbour BioMed (HKG: 2142) announced positive results from its multicenter, open‑label Phase II trial (NCT 05167071)...

Policy / Regulatory

VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement

Fineline Cube Oct 23, 2025

The Office of the National Drug Joint Procurement (ONDJP) published the conclusive enterprise roster for...

Company

Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance

Fineline Cube Oct 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7 % year‑on‑year (YoY)...

Company

Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation

Fineline Cube Oct 22, 2025

Novo Nordisk A/S (NYSE: NVO) announced today that Chairman Helge Lund and six other board...

Company Deals

Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies

Fineline Cube Oct 22, 2025

Innovent Biologics, Inc. (HKG: 1801) today announced a landmark global strategic collaboration with Takeda Pharmaceutical...

Company

Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review

Fineline Cube Oct 22, 2025

Galapagos NV (FRA: GXE) today disclosed that it has decided to wind down its cell‑therapy...

Company Drug

GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D

Fineline Cube Oct 22, 2025

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled...

Company Deals

Rani Therapeutics and Chugai Forge $1.085 Billion Collaboration Deal for Innovative Oral Therapeutic

Fineline Cube Oct 22, 2025

Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan’s Chugai...

Company Drug

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025

Fineline Cube Oct 22, 2025

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...

Company Drug

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors

Fineline Cube Oct 22, 2025

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the National Medical Products Administration (NMPA)...

Company Drug

Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia

Fineline Cube Oct 22, 2025

Huadong Medicine (SHE: 000963) announced that the Investigational New Drug (IND) application for DR10624 Injection,...

Company Drug

AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025

Fineline Cube Oct 22, 2025

AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase III DESTINY‑Breast11 results at...

Company Drug

Indetek Laboratory Secures NMPA Approval for IDT‑001 Gel, a Novel Film‑Forming Therapy for SSTIs

Fineline Cube Oct 22, 2025

Indetek Laboratory announced that the National Medical Products Administration (NMPA) has formally accepted the New...

Company Drug

Fosun‑Henlius Announces 26.8‑Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC

Fineline Cube Oct 22, 2025

Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase III...

Company Drug

Novartis Announces Five‑Year NATALEE Results for Kisqali in HR+/HER2‑ Early Breast Cancer

Fineline Cube Oct 22, 2025

Novartis (NYSE: NVS) presented the five‑year interim analysis of its pivotal Phase III NATALEE study at...

Company Drug

Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type 2 Diabetes

Fineline Cube Oct 21, 2025

Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted...

Posts pagination

1 … 37 38 39 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.